BioLargo Board Buys 470k Options, Betting on PFAS Tech Amid Sharp Stock Decline
BioLargo’s insider option buying signals confidence in its PFAS tech amid steep stock decline and regulatory tailwinds, yet highlights earnings risks and volatility.
4 minutes to read